{
     "PMID": "11250865",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20010719",
     "LR": "20161124",
     "IS": "0007-1188 (Print) 0007-1188 (Linking)",
     "VI": "132",
     "IP": "6",
     "DP": "2001 Mar",
     "TI": "Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice.",
     "PG": "1169-73",
     "AB": "We examined whether acetylcholine release in the hippocampus and striatum and noradrenaline release in the hippocampus is altered in CB(1) receptor-deficient mice. The electrically evoked tritium overflow from hippocampal slices preincubated with [(3)H]-choline was increased by about 100% in CB(1)(-/-) compared to CB(1)(+/+) mice whereas the electrically evoked tritium overflow from striatal slices preincubated with [(3)H]-choline and from hippocampal slices preincubated with [(3)H]-noradrenaline did not differ. The cannabinoid receptor agonist, WIN 55,212-2, inhibited, and the CB(1) receptor antagonist, SR 141716, facilitated, the evoked tritium overflow from hippocampal slices (preincubated with [(3)H]-choline) from CB(1)(+/+) as opposed to CB(1)(-/-) mice. Both drugs did not affect the evoked tritium overflow from striatal slices (preincubated with [(3)H]-choline) and from hippocampal slices (preincubated with [(3)H]-noradrenaline) from CB(1)(+/+) and CB(1)(-/-) mice. The selective increase in acetylcholine release in CB(1)(-/-) mice may indicate that the presynaptic CB(1) receptors on the cholinergic neurones of the mouse hippocampus are tonically activated and/or constitutively active in vivo.",
     "FAU": [
          "Kathmann, M",
          "Weber, B",
          "Zimmer, A",
          "Schlicker, E"
     ],
     "AU": [
          "Kathmann M",
          "Weber B",
          "Zimmer A",
          "Schlicker E"
     ],
     "AD": "Institut fur Pharmakologie und Toxikologie, Rheinische Friedrich-Wilhelms-Universitat Bonn, Reuterstr. 2b, 53113 Bonn, Germany.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "England",
     "TA": "Br J Pharmacol",
     "JT": "British journal of pharmacology",
     "JID": "7502536",
     "RN": [
          "0 (Benzoxazines)",
          "0 (Calcium Channel Blockers)",
          "0 (Morpholines)",
          "0 (Naphthalenes)",
          "0 (Piperidines)",
          "0 (Pyrazoles)",
          "0 (Receptors, Cannabinoid)",
          "0 (Receptors, Drug)",
          "10028-17-8 (Tritium)",
          "5H31GI9502 (Win 55212-2)",
          "N9YNS0M02X (Acetylcholine)",
          "RML78EN3XE (rimonabant)",
          "X4W3ENH1CV (Norepinephrine)"
     ],
     "SB": "IM",
     "MH": [
          "Acetylcholine/*metabolism",
          "Animals",
          "Benzoxazines",
          "Calcium Channel Blockers/pharmacology",
          "Corpus Striatum/drug effects/metabolism",
          "Electric Stimulation",
          "Hippocampus/drug effects/*metabolism",
          "Mice",
          "Mice, Inbred C57BL",
          "Morpholines/pharmacology",
          "Naphthalenes/pharmacology",
          "Norepinephrine/metabolism",
          "Piperidines/pharmacology",
          "Pyrazoles/pharmacology",
          "Receptors, Cannabinoid",
          "Receptors, Drug/deficiency/*metabolism",
          "Tritium"
     ],
     "PMC": "PMC1572680",
     "EDAT": "2001/03/17 10:00",
     "MHDA": "2001/07/20 10:01",
     "CRDT": [
          "2001/03/17 10:00"
     ],
     "PHST": [
          "2001/03/17 10:00 [pubmed]",
          "2001/07/20 10:01 [medline]",
          "2001/03/17 10:00 [entrez]"
     ],
     "AID": [
          "10.1038/sj.bjp.0703987 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Br J Pharmacol. 2001 Mar;132(6):1169-73. doi: 10.1038/sj.bjp.0703987.",
     "term": "hippocampus"
}